BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$336.92 USD
+3.52 (1.06%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $336.80 -0.12 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
BIO 336.92 +3.52(1.06%)
Will BIO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BIO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BIO
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
BIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
National Vision (EYE) Down 6.9% Since Last Earnings Report: Can It Rebound?
Reasons to Retain Bio-Rad (BIO) Stock in Your Portfolio Now
Bio-Rad (BIO) Faces Low BioPharma Demand, Competitive Pressure
Other News for BIO
Biome Australia Sets Virtual Shareholder Meeting
Biome Australia Announces Virtual 2024 AGM
BANK OF NOVA SCOTIA's Strategic Acquisition in Bio-Rad Laboratories Inc
BANK OF NOVA SCOTIA's Strategic Acquisition in Bio-Rad Laboratories Inc
Analysts Offer Insights on Healthcare Companies: Xencor (XNCR), Argenica Therapeutics Ltd (AU:AGN) and Bio-Rad Laboratories (BIO)